Daniel D. Von Hoff, MD, FACP
Clinical Advisor
• Physician in Chief, Distinguished Professor, Director of Clinical Translational Research Division at TGen
• CSO, US Oncology Research
• Professor of Medicine, Mayo Clinic, Scottsdale, AZ
• Recognized expert in Oncology drug development
• PI on numerous phase I-III clinical trials including Abraxane; >620 papers, 137 book chapters
• 2010 David A. Karnofsky Memorial Award from ASCO; Past President of the AACR; Appointed to President
Bush’s National Cancer Advisory Board in 2004-2010
• Founder of ILEX™ Oncology
Sant Chawla, MD, FRACP
Clinical Advisor
• Director, Sarcoma Oncology Center, Santa Monica, CA
• Academic appointments and affiliations: Stanford Univ Medical Center, MD Anderson Cancer Center, David
Geffen School of Medicine UCLA, Keck School of Medicine USC, Cedars Sinai Medical Center
• Extensive Clinical trial experience (>30 yrs) : Phase 1-3. Pazopanib, Denosumab, Ridoforolimus (rapamycin
analog), Palifosfomide, Aldoxorubicin, TH302, belinostat, ofatumumab, AMG655, MEK162 and others